Clinical trials: Benign Esophageal Lesions
Benign Esophageal Lesions
SX ELLA Esophageal Degradable BD Stent System
The SX-ELLA Stent Esophageal Degradable BD (BD Stent) is designed for dilation of benign esophageal lesions, namely: (1) stenosis (peptic, anastomotic or caustic) refractory to standard therapy, (2) achalasia refractory to…
- Trial name
- DESTINY (NCT01337206)
- Testing
- Stenting with ELLA Biodegradable stent, Standard Dilations
- Where
- 8 sites in Belgium, Italy and 3 more
- Volunteers
- 66 people
- Sponsor
- Cook Group Incorporated
Cancer Risk, Cancer Predisposition Syndrome
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member…
- Conditions
- Cancer Risk, Cancer Predisposition Syndrome, Hereditary Cancer Prediction, Childhood Cancer Survivors
- Trial name
- NCT05463796
- Testing
- Samples
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Dana-Farber Cancer Institute
Benign Esophageal Lesions
Use of Metal Stents on Benign Esophageal Lesions
The evaluation of using metal stents as medically indicated for the treatment of benign esophageal lesions.
- Trial name
- NCT01238913
- Testing
- Endoscopy
- Sponsor
- University of Florida
Benign or Early Malignant Lesion of the Distal Esophagus or Gastro-esophageal Junction Requiring Surgical Resection
Feasibility, Safety and QoL After Merendino Procedure
The purpose of this study is to analyse retrospectively the early postoperative and functional outcome of patients (pts) after Merendino procedure for benign or early malignant lesions of the distal part of the esophagus or the…
- Trial name
- MER (NCT02855333)
- Testing
- EORTC and QLQ-C30 / QLQ-OES24 questionnaire
- Where
- Switzerland
- Volunteers
- 26 people
- Sponsor
- Kantonsspital Liestal